Exploring natural anthraquinones as potential MMP2 inhibitors: A computational study

Area of Science:

• Computational drug discovery
• Medicinal chemistry
• Cancer biology

Background:

• Matrix metalloproteinase-2 (MMP2) is crucial for cancer cell progression and invasion.
• Inhibiting MMP2 is a potential strategy for cancer therapy.
• Anthraquinones possess known antineoplastic properties.

Purpose of the Study:

• To computationally screen anthraquinones for MMP2 inhibitory activity.
• To identify potent anthraquinone-based MMP2 inhibitors.
• To compare identified inhibitors with a standard drug, Captopril.

Main Methods:

• Utilized AutoDock 4.0 for binding affinity evaluation of 21 anthraquinones against the MMP2 catalytic domain.
• Assessed Gibbs free binding energy scores to rank ligands.
• Employed Discovery Studio Visualizer to analyze molecular interactions.

Main Results:

• Identified 12 anthraquinones with binding energy scores below -10 kcal/mol.
• Pulmatin (Chrysophanol-8-glucoside) exhibited the highest potency with a binding energy of -12.91 kcal/mol.
• Pulmatin demonstrated picomolar range inhibition of MMP2 activity.

Conclusions:

• Anthraquinones, especially Pulmatin, are effective MMP2 inhibitors.
• This suggests a viable therapeutic approach for cancer treatment.
• Further investigation into Pulmatin as an anticancer agent is warranted.